These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Legha SS; Ring S; Eton O; Bedikian A; Plager C; Papadopoulos N Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387 [TBL] [Abstract][Full Text] [Related]
10. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit? Hofmann MA; Sterry W; Trefzer U Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972 [TBL] [Abstract][Full Text] [Related]
11. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Buzaid AC; Atkins M Clin Cancer Res; 2001 Sep; 7(9):2611-9. PubMed ID: 11555571 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 for the treatment of melanoma. Tarhini AA; Agarwala SS Curr Opin Investig Drugs; 2005 Dec; 6(12):1234-9. PubMed ID: 16370388 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Garbe C Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609 [TBL] [Abstract][Full Text] [Related]
15. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst; 1997 Nov; 89(21):1616-20. PubMed ID: 9362160 [TBL] [Abstract][Full Text] [Related]
16. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738 [TBL] [Abstract][Full Text] [Related]
17. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. Bruzzi P; Del Mastro L; Sormani MP; Bastholt L; Danova M; Focan C; Fountzilas G; Paul J; Rosso R; Venturini M J Clin Oncol; 2005 Aug; 23(22):5117-25. PubMed ID: 15955906 [TBL] [Abstract][Full Text] [Related]
18. New approaches to the systemic treatment of melanoma. Chowdhury S; Vaughan MM; Gore ME Cancer Treat Rev; 1999 Oct; 25(5):259-70. PubMed ID: 10544070 [TBL] [Abstract][Full Text] [Related]
19. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Lui P; Cashin R; Machado M; Hemels M; Corey-Lisle PK; Einarson TR Cancer Treat Rev; 2007 Dec; 33(8):665-80. PubMed ID: 17919823 [TBL] [Abstract][Full Text] [Related]